These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36656578)

  • 1. Assessment of Retinopathy of Prematurity Regression and Reactivation Using an Artificial Intelligence-Based Vascular Severity Score.
    Eilts SK; Pfeil JM; Poschkamp B; Krohne TU; Eter N; Barth T; Guthoff R; Lagrèze W; Grundel M; Bründer MC; Busch M; Kalpathy-Cramer J; Chiang MF; Chan RVP; Coyner AS; Ostmo S; Campbell JP; Stahl A;
    JAMA Netw Open; 2023 Jan; 6(1):e2251512. PubMed ID: 36656578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab.
    Jang JH
    Sci Rep; 2024 Jul; 14(1):15647. PubMed ID: 38977744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.
    Stahl A; Krohne TU; Eter N; Oberacher-Velten I; Guthoff R; Meltendorf S; Ehrt O; Aisenbrey S; Roider J; Gerding H; Jandeck C; Smith LEH; Walz JM;
    JAMA Pediatr; 2018 Mar; 172(3):278-286. PubMed ID: 29309486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial.
    Fleck BW; Reynolds JD; Zhu Q; Lepore D; Marlow N; Stahl A; Li J; Weisberger A; Fielder AR;
    Ophthalmol Retina; 2022 Jul; 6(7):628-637. PubMed ID: 35202890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External Validation of a Retinopathy of Prematurity Screening Model Using Artificial Intelligence in 3 Low- and Middle-Income Populations.
    Coyner AS; Oh MA; Shah PK; Singh P; Ostmo S; Valikodath NG; Cole E; Al-Khaled T; Bajimaya S; K C S; Chuluunbat T; Munkhuu B; Subramanian P; Venkatapathy N; Jonas KE; Hallak JA; Chan RVP; Chiang MF; Kalpathy-Cramer J; Campbell JP
    JAMA Ophthalmol; 2022 Aug; 140(8):791-798. PubMed ID: 35797036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity.
    Chang E; Josan AS; Purohit R; Patel CK; Xue K
    Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Smartphone-Based Telescreening for Retinopathy of Prematurity With and Without Artificial Intelligence in India.
    Young BK; Cole ED; Shah PK; Ostmo S; Subramaniam P; Venkatapathy N; Tsai ASH; Coyner AS; Gupta A; Singh P; Chiang MF; Kalpathy-Cramer J; Chan RVP; Campbell JP
    JAMA Ophthalmol; 2023 Jun; 141(6):582-588. PubMed ID: 37166816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab.
    Lyu J; Zhang Q; Jin H; Xu Y; Chen C; Ji X; Zhang X; Rao Y; Zhao P
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1469-1477. PubMed ID: 29948178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Examination Risk Prediction of Severe Retinopathy of Prematurity.
    Coyner AS; Chen JS; Singh P; Schelonka RL; Jordan BK; McEvoy CT; Anderson JE; Chan RVP; Sonmez K; Erdogmus D; Chiang MF; Kalpathy-Cramer J; Campbell JP
    Pediatrics; 2021 Dec; 148(6):. PubMed ID: 34814160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.
    Bassiouny RM; Gaafar WM; El Nokrashy A; Abdelhameed AG; Attallah EA; Elgharieb AG; Bassiouny MR
    Eye (Lond); 2022 Nov; 36(11):2137-2143. PubMed ID: 34711941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiologic Evaluation of Retinopathy of Prematurity Severity in a Large Telemedicine Program in India Using Artificial Intelligence.
    deCampos-Stairiker MA; Coyner AS; Gupta A; Oh M; Shah PK; Subramanian P; Venkatapathy N; Singh P; Kalpathy-Cramer J; Chiang MF; Chan RVP; Campbell JP
    Ophthalmology; 2023 Aug; 130(8):837-843. PubMed ID: 37030453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study.
    Stahl A; Bründer MC; Lagrèze WA; Molnár FE; Barth T; Eter N; Guthoff R; Krohne TU; Pfeil JM;
    Acta Ophthalmol; 2022 Feb; 100(1):e91-e99. PubMed ID: 33742551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
    Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P
    Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
    Gunay M; Sukgen EA; Celik G; Kocluk Y
    Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
    Stahl A; Sukgen EA; Wu WC; Lepore D; Nakanishi H; Mazela J; Moshfeghi DM; Vitti R; Athanikar A; Chu K; Iveli P; Zhao F; Schmelter T; Leal S; Köfüncü E; Azuma N;
    JAMA; 2022 Jul; 328(4):348-359. PubMed ID: 35881122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.